Twist Bioscience Corporation (BIT:1TWST)

Italy flag Italy · Delayed Price · Currency is EUR
41.84
-0.37 (-0.88%)
At close: Mar 5, 2026
Market Cap2.48B -9.8%
Revenue (ttm)333.49M +18.6%
Net Income-65.23M
EPS-1.08
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40
Average Volume14
Open42.21
Previous Close42.21
Day's Range42.21 - 42.21
52-Week Range19.50 - 46.37
Betan/a
RSI52.24
Earnings DateMay 4, 2026

About Twist Bioscience

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 979
Stock Exchange Borsa Italiana
Ticker Symbol 1TWST
Full Company Profile

Financial Performance

In fiscal year 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.

Financial numbers in USD Financial Statements

News

Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript

Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript

16 days ago - Seeking Alpha

Twist Bioscience to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...

16 days ago - Business Wire

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement wi...

17 days ago - Business Wire

Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twis...

24 days ago - Business Wire

Twist Bioscience: Liquid Biopsy And AI Tailwinds

Twist Bioscience's stock has moved high in recent months, driven by optimism related to AI-enabled drug discovery and MRD testing. Q1 growth was modest, due in large part to an air pocket in demand ca...

24 days ago - Seeking Alpha

These Analysts Increase Their Forecasts On Twist Bioscience After Q1 Results

Twist Bioscience Corporation (NASDAQ: TWST) on Monday posted better-than-expected sales for the first quarter.

4 weeks ago - Benzinga

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value bi...

4 weeks ago - Business Wire

Why Is Twist Bioscience Stock Soaring Monday?

Twist Bioscience Corporation (NASDAQ: TWST) on Monday posted first-quarter 2026 results of a loss of 50 cents per share, in line with the Wall Street expectations.

4 weeks ago - Benzinga

Twist Bioscience: Ingenious Product Still Lacks Compelling Use Cases

Twist Bioscience Corporation reported Q1 2026 revenue of $103.7M, up 17% YoY, and raised full-year guidance to $435–$440M. TWST targets adjusted EBITDA breakeven in Q4 2026, with gross margin expected...

4 weeks ago - Seeking Alpha

Twist Bioscience Corporation (TWST) Q1 2026 Earnings Call Transcript

Twist Bioscience Corporation (TWST) Q1 2026 Earnings Call Transcript

4 weeks ago - Seeking Alpha

Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the...

4 weeks ago - Business Wire

Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

7 weeks ago - Seeking Alpha

Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quar...

7 weeks ago - Business Wire

Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...

2 months ago - Business Wire

Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciar...

3 months ago - Business Wire

Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to suppo...

3 months ago - Business Wire

Twist Bioscience Is Bent, Not Broken: Near-Term Strain, Long-Term Strength

Twist's revenue growth continues to moderate due to macro headwinds and temporary challenges in the NGS business. The Biopharma segment is reaccelerating, though, driven by AI-enabled drug discovery c...

3 months ago - Seeking Alpha

Can Twist Bioscience Drop More?

Twist Bioscience (TWST) stock has decreased by 10.1% in one day. The recent downturn signifies renewed worries regarding wider-than-anticipated losses and ambiguous profitability guidance, but signifi...

3 months ago - Forbes

Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript

Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript

4 months ago - Seeking Alpha

Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses

Twist Bioscience Corporation (NASDAQ: TWST) on Friday posted mixed fourth-quarter results, reporting a loss of 45 cents per share, slightly wider than the consensus estimate of a 43-cent loss.

4 months ago - Benzinga

Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the...

4 months ago - Business Wire

Top Wall Street Forecasters Revamp Twist Bioscience Expectations Ahead Of Q4 Earnings

Twist Bioscience Corporation (NASDAQ: TWST) will release fourth-quarter earnings before the opening bell on Friday, Nov. 14.

4 months ago - Benzinga

Twist Bioscience to Present at 7th Annual Wolfe Research Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...

4 months ago - Business Wire

Twist Bioscience to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results on Friday, November 14, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the ...

4 months ago - Business Wire

Twist Bioscience and Element Biosciences Advance Collaboration with Launch of New Trinity Freestyle™ Sequencing Workflow for the AVITI™ System

SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, and Element Biosciences, Inc., a company democratizin...

5 months ago - Business Wire